Health state utilities and quality of life in patients with hepatitis B

Canadian Journal of Gastroenterology

Volumn 26, Issue 7, 2012, Pages 445-451

  Woo, Gloria ^a,b   Tomlinson, George ^a,c,d   Yim, Colina ^b,e   Lilly, Les ^d   Therapondos, George ^f   Wong, David K H ^e,g   Ungar, Wendy ^c,h   Einarson, Thomas R ^b   Sherman, Morris ^d,g   Heathcote, E Jenny ^e,g   Krahn, Murray ^a,b,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

^f Oschner Clinic Foundation   (United States)

^g UNIVERSITY OF TORONTO   (Canada)

^h HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Health utilities; Hepatitis B; Quality of life

Indexed keywords

ADEFOVIR; ENTECAVIR; LAMIVUDINE; TELBIVUDINE; TENOFOVIR;

ADULT; ARTICLE; DECOMPENSATED LIVER CIRRHOSIS; FEMALE; HEALTH CARE UTILIZATION; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RISK FACTOR;

EID: 84863757665     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2012/736452     Document Type: Article

References (27)

1. Custer B, Sullivan SD, Hazlet TK, et al. Global epidemiology of hepatitis B virus. J Clin Gastroenterol 2004;38(10 Suppl 3):S158-68.
2. Leber A, Sherman M, Estimation of immigration related chronic hepatitis B infection and hepatocellular carcinoma development in Canada from 1981-2006 (S022). Canadian Digestive Diseases Week, February 27 to March 2, 2009, Banff, Alberta.
3. Kim WR. Epidemiology of hepatitis B in the United States. Hepatology 2009;49(5 Suppl):S28-34.
4. Weinbaum CM, Mast EE, Ward JW. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. Hepatology 2009;49(5 Suppl):S35-44.
5. Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol 2005;34(Suppl 1):S1-3. (Pubitemid 43197742)
6. Wang WL, Wang CJ, Tseng HF. Comparing knowledge, health beliefs, and self-efficacy toward hepatitis B prevention among university students with different hepatitis B virus infectious statuses. J Nurs Res 2009;17:10-9.
7. Kanwal F, Farid M, Martin P, et al. Treatment alternatives for hepatitis B cirrhosis: A cost-effectiveness analysis. Am J Gastroenterol 2006;101:2076-89. (Pubitemid 44337634)
8. Takeda A, Jones J, Shepherd J, et al. A systematic review and economic evaluation of adefovir dipivoxil and pegylated interferon-alpha-2a for the treatment of chronic hepatitis B. J Viral Hepat 2007;14:75-88. (Pubitemid 46146702)
9. Ong SC, Mak B, Aung MO, et al. Health-related quality of life in chronic hepatitis B patients. Hepatology 2008;47:1108-17. (Pubitemid 351547897)
10. Bondini S, Kallman J, Dan A, et al. Health-related quality of life in patients with chronic hepatitis B. Liver Int 2007;27:1119-25. (Pubitemid 47399447)
11. Dan AA, Kallman JB, Srivastava R, et al. Impact of chronic liver disease and cirrhosis on health utilities using SF-6D and the health utility index. Liver Transpl 2008;14:321-6. (Pubitemid 351425486)
12. Horsman J, Furlong W, Feeny D, et al. The Health Utilities Index (HUI): Concepts, measurement properties and applications. Health Qual Life Outcomes 2003;1:54.
13. Luo N, Chew LH, Fong KY, et al. Do English and Chinese EQ-5D versions demonstrate measurement equivalence? An exploratory study. Health Qual Life Outcomes 2003;1:7.
14. Luo N, Chew LH, Fong KY, et al. Validity and reliability of the EQ-5D self-report questionnaire in English-speaking Asian patients with rheumatic diseases in Singapore. Qual Life Res 2003;12:87-92. (Pubitemid 36223009)
15. Li L, Wang HM, Shen Y. Chinese SF-36 Health Survey: Translation, cultural adaptation, validation, and normalisation. J Epidemiol Community Health 2003;57:259-63. (Pubitemid 36399113)
16. Lam ET, Lam CL, Lai CL, et al. Psychometrics of the chronic liver disease questionnaire for Southern Chinese patients with chronic hepatitis B virus infection. World J Gastroenterol 2009;15:3288-97.
17. Orito E, Ichida T, Sakugawa H, et al. Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology 2001;34:590-4. (Pubitemid 32786652)
18. Levy AR, Kowdley KV, Iloeje U, et al. The impact of chronic hepatitis B on quality of life: A multinational study of utilities from infected and uninfected persons. Value Health 2008;11:527-38. (Pubitemid 351712982)
19. Charlson ME, P. Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40:373-83.
20. Ware JE, Kosinski M, Dewey JE, How to score version two of the SF-36 Health Survey. Lincoln: Quality Metric, 2009.
21. Johnson JA, Pickard AS, Comparison of the EQ-5D and SF-12 health surveys in a general population survey in Alberta, Canada. Med Care 2000;38:115-21.
22. Mittmann N, Trakas K, Risebrough N, et al. Utility scores for chronic conditions in a community-dwelling population. Pharmacoeconomics 1999;15:369-76. (Pubitemid 29190028)
23. Chong CA, Gulamhussein A, Heathcote EJ, et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003;98:630-8. (Pubitemid 36348537)
24. Menzel P, Dolan P, Richardson J, et al. The role of adaptation to disability and disease in health state valuation: A preliminary normative analysis. Soc Sci Med 2002;55:2149-58. (Pubitemid 36158948)
25. Sullivan SD, Veenstra DL, Chen PJ, et al. Cost-effectiveness of peginterferon alpha-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan. J Gastroenterol Hepatol 2007;22:1494-9. (Pubitemid 47274568)
26. Veenstra DL, Sullivan SD, Lai MY, et al. HBeAg-negative chronic hepatitis B: Cost-effectiveness of peginterferon alfa-2a compared to lamivudine in Taiwan. Value Health 2008;11:131-8. (Pubitemid 351473598)
27. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-31.